ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer. AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced ...

Median duration of follow-up was nearly 2.5 years (29.2 months). As of the data cut-off, 302 (39.6%) patients remained on treatment, 174 in the ENHERTUplus pertuzumab arm and 128 in the THP arm.. The ...

TOKYO & BASKING RIDGE, N.J. - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) announced positive results from the phase 3 DESTINY-Breast09 trial, indicating that their drug ENHERTU®, ...

AstraZeneca's ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab deruxtecan) plus rilvegostomig or pembrolizumab versus platinum-based ...

ENHERTU is a HER2-directed antibody drug conjugate (ADC) developed by Daiichi Sankyo and commercialized in partnership with AstraZeneca. It is approved in over 80 countries as a second-line treatment ...

Enhertu (6.4mg/kg) is approved in more than 70 countries worldwide for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or 2+/ISH+) gastric or gastroesophageal ...

(Alliance News) - AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus ...

Enhertu is an important drug, but the decision will not be straightforward, said Matthew Goetz, a Mayo Clinic oncologist. That’s because the regimen it would replace is well tolerated.

Enhertu (6.4 mg/kg) is approved in more than 70 countries worldwide for the treatment of adult patients with locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.